Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 10/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19325770 | 0.85 | FOLH1 (0.50) | TP53HTTIDO1FOLH1ALDH1A1 | |
| SCHEMBL23453516 | 0.83 | TP53 (0.59) | TP53HTTFOLH1ALDH1A1ALOX15 | |
| SCHEMBL7052412 | 0.82 | IDO1 (0.52) | IDO1ALDH1A1 | |
| SCHEMBL20798280 | 0.82 | MRGPRX4 (0.55) | IDO1ALDH1A1MRGPRX4TSHR | |
| SCHEMBL623624 | 0.82 | TP53 (0.57) | TP53HTTFOLH1ALDH1A1ALOX15 | |
| SCHEMBL722641 | 0.81 | HTT (0.53) | TP53HTTFOLH1ALDH1A1ALOX15 | |
| SCHEMBL31617745 | 0.80 | HTT (0.56) | TP53HTTFOLH1ALDH1A1ALOX15 | |
| SCHEMBL3098697 | 0.80 | TP53 (0.60) | TP53HTTFOLH1ALDH1A1ALOX15 | |
| SCHEMBL28980885 | 0.80 | TP53 (0.56) | TP53HTTFOLH1ALDH1A1ALOX15 | |
| SCHEMBL8481208 | 0.80 | HTT (0.56) | TP53HTTFOLH1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991013062-A2 | SUBSTITUTED 1-(ALKOXY-IMINOALKYL)IMIDAZOLE DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-09-05 | — | — | WO | claimed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-5856334-A | ANTAGONIST FOR EOSINOPHILS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0773219-A1 | IMIDAZOQUINOLINE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| EP-0469125-A1 | SUBSTITUTED 1-(ALKOXY-IMINOALKYL)IMIDAZOLE DERIVATIVES. | ERBA FARMITALIA (IT) | 1992-02-05 | — | — | EP | disclosed |
| WO-1991013062-A2 | SUBSTITUTED 1-(ALKOXY-IMINOALKYL)IMIDAZOLE DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | TP53 719/4885HTT 3243/4885IDO1 1/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | TP53 748/4885HTT 3609/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.